Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 208.81 Million EUR | 37.04% |
| 2022 | 152.38 Million EUR | 32.9% |
| 2021 | 114.65 Million EUR | 8.73% |
| 2020 | 105.45 Million EUR | 23.75% |
| 2019 | 85.21 Million EUR | 47.94% |
| 2018 | 57.6 Million EUR | -19.43% |
| 2017 | 71.49 Million EUR | -13.34% |
| 2016 | 82.5 Million EUR | -19.32% |
| 2015 | 102.25 Million EUR | 39.78% |
| 2014 | 73.15 Million EUR | 2.63% |
| 2013 | 71.28 Million EUR | 961.69% |
| 2012 | 6.71 Million EUR | -1.21% |
| 2011 | 6.79 Million EUR | -0.03% |
| 2010 | 6.79 Million EUR | 6.47% |
| 2009 | 6.38 Million EUR | 37.85% |
| 2008 | 4.63 Million EUR | 25.53% |
| 2007 | 3.69 Million EUR | 10.58% |
| 2006 | 3.33 Million EUR | 9.02% |
| 2005 | 3.06 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 211.67 Million EUR | 1.37% |
| 2024 Q2 | 209.63 Million EUR | -0.96% |
| 2023 Q2 | 149.23 Million EUR | -2.29% |
| 2023 Q4 | 208.81 Million EUR | 7.36% |
| 2023 FY | 208.81 Million EUR | 37.04% |
| 2023 Q3 | 194.5 Million EUR | 30.34% |
| 2023 Q1 | 152.72 Million EUR | 0.23% |
| 2022 Q2 | 133.52 Million EUR | 15.58% |
| 2022 Q1 | 115.52 Million EUR | 0.75% |
| 2022 Q4 | 152.38 Million EUR | -5.72% |
| 2022 FY | 152.38 Million EUR | 32.9% |
| 2022 Q3 | 161.61 Million EUR | 21.04% |
| 2021 Q2 | 111.48 Million EUR | 5.17% |
| 2021 FY | 114.65 Million EUR | 8.73% |
| 2021 Q1 | 106 Million EUR | 0.53% |
| 2021 Q4 | 114.65 Million EUR | 0.0% |
| 2020 Q3 | 111.26 Million EUR | -1.49% |
| 2020 Q4 | 105.45 Million EUR | -5.23% |
| 2020 Q2 | 112.95 Million EUR | 13.76% |
| 2020 Q1 | 99.28 Million EUR | 16.51% |
| 2020 FY | 105.45 Million EUR | 23.75% |
| 2019 FY | 85.21 Million EUR | 47.94% |
| 2019 Q1 | 76.49 Million EUR | 32.81% |
| 2019 Q4 | 85.21 Million EUR | 1.66% |
| 2019 Q3 | 83.82 Million EUR | 13.7% |
| 2019 Q2 | 73.71 Million EUR | -3.64% |
| 2018 FY | 57.6 Million EUR | -19.43% |
| 2018 Q1 | 66.51 Million EUR | -6.97% |
| 2018 Q4 | 57.6 Million EUR | -4.55% |
| 2018 Q3 | 60.34 Million EUR | -2.65% |
| 2018 Q2 | 61.98 Million EUR | -6.81% |
| 2017 Q4 | 71.49 Million EUR | 2.27% |
| 2017 FY | 71.49 Million EUR | -13.34% |
| 2017 Q2 | 74.07 Million EUR | -1.69% |
| 2017 Q1 | 75.34 Million EUR | -8.67% |
| 2017 Q3 | 69.91 Million EUR | -5.62% |
| 2016 Q4 | 82.5 Million EUR | 2.87% |
| 2016 FY | 82.5 Million EUR | -19.32% |
| 2016 Q3 | 80.2 Million EUR | -0.33% |
| 2016 Q2 | 80.46 Million EUR | -2.38% |
| 2016 Q1 | 82.42 Million EUR | -19.39% |
| 2015 Q4 | 102.25 Million EUR | 16.21% |
| 2015 Q1 | 90.84 Million EUR | 24.18% |
| 2015 FY | 102.25 Million EUR | 39.78% |
| 2015 Q2 | 89.25 Million EUR | -1.75% |
| 2015 Q3 | 87.99 Million EUR | -1.41% |
| 2014 Q4 | 73.15 Million EUR | 2.24% |
| 2014 FY | 73.15 Million EUR | 2.63% |
| 2014 Q3 | 71.55 Million EUR | 1.36% |
| 2014 Q2 | 70.59 Million EUR | -1.03% |
| 2014 Q1 | 71.32 Million EUR | 0.06% |
| 2013 Q4 | 71.28 Million EUR | 38.16% |
| 2013 FY | 71.28 Million EUR | 961.69% |
| 2013 Q3 | 51.59 Million EUR | -35.02% |
| 2013 Q2 | 79.39 Million EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 FY | 6.71 Million EUR | -1.21% |
| 2012 Q2 | 6.21 Million EUR | 0.0% |
| 2012 Q4 | 6.71 Million EUR | 0.0% |
| 2011 FY | 6.79 Million EUR | -0.03% |
| 2011 Q2 | 7.61 Million EUR | 0.0% |
| 2011 Q4 | 6.79 Million EUR | 0.0% |
| 2010 FY | 6.79 Million EUR | 6.47% |
| 2010 Q2 | 6.94 Million EUR | 0.0% |
| 2010 Q4 | 6.79 Million EUR | 0.0% |
| 2009 Q4 | 6.38 Million EUR | 0.0% |
| 2009 FY | 6.38 Million EUR | 37.85% |
| 2008 FY | 4.63 Million EUR | 25.53% |
| 2007 FY | 3.69 Million EUR | 10.58% |
| 2006 FY | 3.33 Million EUR | 9.02% |
| 2005 FY | 3.06 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -406.798% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -4965.943% |
| SQZ Biotechnologies Company | 27.47 Million USD | -660.133% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -381.442% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -601.498% |
| Mesoblast Limited | 118.7 Million USD | -75.919% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -21920.709% |
| Genus plc | 233.1 Million USD | 10.418% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -7025.882% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -15441.715% |
| Marizyme, Inc. | 18.71 Million USD | -1015.619% |
| ContraFect Corporation | 2.88 Million USD | -7148.039% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -27742.133% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -154022.536% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -14337.755% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -8877.646% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -3590.402% |
| MultiCell Technologies, Inc. | 202.58 USD | -103078190.058% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -263.228% |
| EV Biologics, Inc. | 1.49 Million USD | -13869.952% |
| Q BioMed Inc. | 4.1 Million USD | -4980.705% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -530.845% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -33041.346% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -16899.563% |
| Biomind Labs Inc. | 735.54 Thousand USD | -28289.405% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -21.727% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -1506.648% |
| Skye Bioscience, Inc. | 4.61 Million USD | -4424.463% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -23413.621% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -147454.375% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -3456.682% |
| IMV Inc. | 28.88 Million USD | -622.95% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -811813.371% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -9146.27% |
| GB Sciences, Inc. | 1.75 Million USD | -11769.219% |
| Alpha Cognition Inc. | 1.22 Million USD | -17010.848% |
| HST Global, Inc. | 98.31 Thousand USD | -212286.212% |
| CSL Limited | 12.18 Billion USD | 98.286% |
| Halberd Corporation | 150 Thousand USD | -139110.667% |
| Enzolytics Inc. | 996.33 Thousand USD | -20858.349% |
| Resverlogix Corp. | 6.49 Million USD | -3117.008% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -43631.099% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -81598.958% |
| argenx SE | 20 Million USD | -944.08% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -358.332% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -7609.077% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2042110.269% |
| Genscript Biotech Corporation | 417.73 Million USD | 50.013% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -103987.411% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -8608.926% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -90970.299% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -208.704% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -6800.291% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -57951.208% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -927.233% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -140371.161% |
| BioStem Technologies, Inc. | 4.71 Million USD | -4332.127% |
| ONE Bio Corp. | 19.71 Million USD | -959.172% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -83365.637% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -83856.256% |
| Agentix Corp. | 50 Thousand USD | -417532.0% |
| LadRx Corporation | 33.6 Thousand USD | -621265.232% |
| Cell Source, Inc. | 9.25 Million USD | -2156.452% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -27513.713% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -27513.713% |
| NovAccess Global Inc. | 2.19 Million USD | -9392.154% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -2852.377% |
| Itoco Inc. | 228.37 Thousand USD | -91334.777% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -98876.656% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -4090.568% |
| Kadimastem Ltd | 891.22 Thousand USD | -23330.196% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -51863.797% |
| CytoDyn Inc. | 30.07 Million USD | -594.294% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -43018.501% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -59248.524% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -2570.295% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -170362.041% |
| Rebus Holdings, Inc. | 310 Thousand USD | -67260.0% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -4309.79% |
| International Stem Cell Corporation | 4.17 Million USD | -4897.989% |
| Bioxytran, Inc. | 1.92 Million USD | -10747.584% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -334471.323% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -9474.763% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -2411.015% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -2332.335% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -13324.546% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -77816.418% |
| Neutra Corp. | 54.15 Thousand USD | -385482.392% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -11310.71% |
| PureTech Health plc | 25.51 Million USD | -718.501% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -16956.981% |
| IXICO plc | 472.02 Thousand USD | -44138.522% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -1247.113% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -235.377% |
| CSL Limited | 12.18 Billion USD | 98.286% |
| Cellectis S.A. | 92.77 Million USD | -125.074% |